Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema, a Serious Cause of Vision Loss
October 13, 2026
October 13, 2026
SOUTH SAN FRANCISCO, California, Oct. 13 -- Genentech, a member of the Roche Group, issued the following news release:
* * *
Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
* In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks
* UME is the leading cause of mode . . .
* * *
Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
* In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks
* UME is the leading cause of mode . . .